0.013556
0.000000
0.000000
0.000000
0.013784
0.000000
0.000000
0.000000
0.018498
0.00000
0.00000
0.00000
Schulze-Gahmen, U.
Meijer, L.
Kim, S.-H.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
4
90.00
90.00
90.00
73.770
72.550
54.060
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C15 H18 N6 O
298.343
OLOMOUCINE
non-polymer
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proteins
PSFGEY
0867
0887-3585
22
378
10.1002/PROT.340220408
7479711
Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine.
1995
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
287.0
1
MIRRORS
IMAGE PLATE
RIGAKU IMAGE PLATE
SINGLE WAVELENGTH
M
x-ray
1
1.5418
1.0
1.5418
ROTATING ANODE
RIGAKU RU200
INHIBITOR BOUND IN POCKET BETWEEN 2 DOMAINS
33976.488
CYCLIN-DEPENDENT KINASE 2
2.7.1.37
1
man
polymer
298.343
OLOMOUCINE
1
syn
non-polymer
18.015
water
76
nat
water
P33 PROTEIN KINASE, CDK2
no
no
MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVF
EFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYT
HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF
PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL
MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVF
EFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYT
HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF
PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL
C
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
FALL ARMYWORM
sample
9606
HOMO SAPIENS
SF9
7108
SPODOPTERA FRUGIPERDA
BACULOVIRUS
1
2.13
42.22
repository
Initial release
Database references
Derived calculations
Non-polymer description
Other
Source and taxonomy
Structure summary
Version format compliance
1
0
2005-01-14
1
1
2014-02-05
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
HUMAN CYCLIN-DEPENDENT KINASE 2
HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE
HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND
CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2
CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX
CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR
THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR
CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN COMPLEX WITH THE INHIBITOR H717
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
HUMAN CYCLIN-DEPENDENT KINASE 2
HUMAN CYCLIN-DEPENDENT KINASE 2
PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
P27(KIP1)/CYCLIN A/CDK2 COMPLEX
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE
CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365
CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)BENZENESULFONAMIDE
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- DIHYDRO-1H-INDOLE
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P-F-PHE)-NH2
CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2
CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2
CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2
CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2
THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS)
CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR
THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)-AMINE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)-AMINE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1,4-DIAMINE
PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2
CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
PDBE
Y
PDBE
2004-06-14
REL
OLO
OLOMOUCINE
HOH
water
FUNCTION: PROBABLY INVOLVED IN THE CONTROL OF THE
CELL CYCLE. INTERACTS WITH CYCLINS A, B3, D, OR E.
ACTIVITY OF CDK2 IS MAXIMAL DURING S PHASE AND G2.
CATALYTIC ACTIVITY: ATP + A PROTEIN = ADP + A PHOSPHOPROTEIN.
OLO
1299
2
OLO
OLO
1299
C
HOH
2001
3
HOH
HOH
2001
C
HOH
2002
3
HOH
HOH
2002
C
HOH
2003
3
HOH
HOH
2003
C
HOH
2004
3
HOH
HOH
2004
C
HOH
2005
3
HOH
HOH
2005
C
HOH
2006
3
HOH
HOH
2006
C
HOH
2007
3
HOH
HOH
2007
C
HOH
2008
3
HOH
HOH
2008
C
HOH
2009
3
HOH
HOH
2009
C
HOH
2010
3
HOH
HOH
2010
C
HOH
2011
3
HOH
HOH
2011
C
HOH
2012
3
HOH
HOH
2012
C
HOH
2013
3
HOH
HOH
2013
C
HOH
2014
3
HOH
HOH
2014
C
HOH
2015
3
HOH
HOH
2015
C
HOH
2016
3
HOH
HOH
2016
C
HOH
2017
3
HOH
HOH
2017
C
HOH
2018
3
HOH
HOH
2018
C
HOH
2019
3
HOH
HOH
2019
C
HOH
2020
3
HOH
HOH
2020
C
HOH
2021
3
HOH
HOH
2021
C
HOH
2022
3
HOH
HOH
2022
C
HOH
2023
3
HOH
HOH
2023
C
HOH
2024
3
HOH
HOH
2024
C
HOH
2025
3
HOH
HOH
2025
C
HOH
2026
3
HOH
HOH
2026
C
HOH
2027
3
HOH
HOH
2027
C
HOH
2028
3
HOH
HOH
2028
C
HOH
2029
3
HOH
HOH
2029
C
HOH
2030
3
HOH
HOH
2030
C
HOH
2031
3
HOH
HOH
2031
C
HOH
2032
3
HOH
HOH
2032
C
HOH
2033
3
HOH
HOH
2033
C
HOH
2034
3
HOH
HOH
2034
C
HOH
2035
3
HOH
HOH
2035
C
HOH
2036
3
HOH
HOH
2036
C
HOH
2037
3
HOH
HOH
2037
C
HOH
2038
3
HOH
HOH
2038
C
HOH
2039
3
HOH
HOH
2039
C
HOH
2040
3
HOH
HOH
2040
C
HOH
2041
3
HOH
HOH
2041
C
HOH
2042
3
HOH
HOH
2042
C
HOH
2043
3
HOH
HOH
2043
C
HOH
2044
3
HOH
HOH
2044
C
HOH
2045
3
HOH
HOH
2045
C
HOH
2046
3
HOH
HOH
2046
C
HOH
2047
3
HOH
HOH
2047
C
HOH
2048
3
HOH
HOH
2048
C
HOH
2049
3
HOH
HOH
2049
C
HOH
2050
3
HOH
HOH
2050
C
HOH
2051
3
HOH
HOH
2051
C
HOH
2052
3
HOH
HOH
2052
C
HOH
2053
3
HOH
HOH
2053
C
HOH
2054
3
HOH
HOH
2054
C
HOH
2055
3
HOH
HOH
2055
C
HOH
2056
3
HOH
HOH
2056
C
HOH
2057
3
HOH
HOH
2057
C
HOH
2058
3
HOH
HOH
2058
C
HOH
2059
3
HOH
HOH
2059
C
HOH
2060
3
HOH
HOH
2060
C
HOH
2061
3
HOH
HOH
2061
C
HOH
2062
3
HOH
HOH
2062
C
HOH
2063
3
HOH
HOH
2063
C
HOH
2064
3
HOH
HOH
2064
C
HOH
2065
3
HOH
HOH
2065
C
HOH
2066
3
HOH
HOH
2066
C
HOH
2067
3
HOH
HOH
2067
C
HOH
2068
3
HOH
HOH
2068
C
HOH
2069
3
HOH
HOH
2069
C
HOH
2070
3
HOH
HOH
2070
C
HOH
2071
3
HOH
HOH
2071
C
HOH
2072
3
HOH
HOH
2072
C
HOH
2073
3
HOH
HOH
2073
C
HOH
2074
3
HOH
HOH
2074
C
HOH
2075
3
HOH
HOH
2075
C
HOH
2076
3
HOH
HOH
2076
C
MET
1
n
1
MET
1
C
GLU
2
n
2
GLU
2
C
ASN
3
n
3
ASN
3
C
PHE
4
n
4
PHE
4
C
GLN
5
n
5
GLN
5
C
LYS
6
n
6
LYS
6
C
VAL
7
n
7
VAL
7
C
GLU
8
n
8
GLU
8
C
LYS
9
n
9
LYS
9
C
ILE
10
n
10
ILE
10
C
GLY
11
n
11
GLY
11
C
GLU
12
n
12
GLU
12
C
GLY
13
n
13
GLY
13
C
THR
14
n
14
THR
14
C
TYR
15
n
15
TYR
15
C
GLY
16
n
16
GLY
16
C
VAL
17
n
17
VAL
17
C
VAL
18
n
18
VAL
18
C
TYR
19
n
19
TYR
19
C
LYS
20
n
20
LYS
20
C
ALA
21
n
21
ALA
21
C
ARG
22
n
22
ARG
22
C
ASN
23
n
23
ASN
23
C
LYS
24
n
24
LYS
24
C
LEU
25
n
25
LEU
25
C
THR
26
n
26
THR
26
C
GLY
27
n
27
GLY
27
C
GLU
28
n
28
GLU
28
C
VAL
29
n
29
VAL
29
C
VAL
30
n
30
VAL
30
C
ALA
31
n
31
ALA
31
C
LEU
32
n
32
LEU
32
C
LYS
33
n
33
LYS
33
C
LYS
34
n
34
LYS
34
C
ILE
35
n
35
ILE
35
C
ARG
36
n
36
ARG
36
C
n
37
37
C
n
38
38
C
n
39
39
C
n
40
40
C
n
41
41
C
n
42
42
C
n
43
43
C
VAL
44
n
44
VAL
44
C
PRO
45
n
45
PRO
45
C
SER
46
n
46
SER
46
C
THR
47
n
47
THR
47
C
ALA
48
n
48
ALA
48
C
ILE
49
n
49
ILE
49
C
ARG
50
n
50
ARG
50
C
GLU
51
n
51
GLU
51
C
ILE
52
n
52
ILE
52
C
SER
53
n
53
SER
53
C
LEU
54
n
54
LEU
54
C
LEU
55
n
55
LEU
55
C
LYS
56
n
56
LYS
56
C
GLU
57
n
57
GLU
57
C
LEU
58
n
58
LEU
58
C
ASN
59
n
59
ASN
59
C
HIS
60
n
60
HIS
60
C
PRO
61
n
61
PRO
61
C
ASN
62
n
62
ASN
62
C
ILE
63
n
63
ILE
63
C
VAL
64
n
64
VAL
64
C
LYS
65
n
65
LYS
65
C
LEU
66
n
66
LEU
66
C
LEU
67
n
67
LEU
67
C
ASP
68
n
68
ASP
68
C
VAL
69
n
69
VAL
69
C
ILE
70
n
70
ILE
70
C
HIS
71
n
71
HIS
71
C
THR
72
n
72
THR
72
C
GLU
73
n
73
GLU
73
C
ASN
74
n
74
ASN
74
C
LYS
75
n
75
LYS
75
C
LEU
76
n
76
LEU
76
C
TYR
77
n
77
TYR
77
C
LEU
78
n
78
LEU
78
C
VAL
79
n
79
VAL
79
C
PHE
80
n
80
PHE
80
C
GLU
81
n
81
GLU
81
C
PHE
82
n
82
PHE
82
C
LEU
83
n
83
LEU
83
C
HIS
84
n
84
HIS
84
C
GLN
85
n
85
GLN
85
C
ASP
86
n
86
ASP
86
C
LEU
87
n
87
LEU
87
C
LYS
88
n
88
LYS
88
C
LYS
89
n
89
LYS
89
C
PHE
90
n
90
PHE
90
C
MET
91
n
91
MET
91
C
ASP
92
n
92
ASP
92
C
ALA
93
n
93
ALA
93
C
SER
94
n
94
SER
94
C
ALA
95
n
95
ALA
95
C
LEU
96
n
96
LEU
96
C
THR
97
n
97
THR
97
C
GLY
98
n
98
GLY
98
C
ILE
99
n
99
ILE
99
C
PRO
100
n
100
PRO
100
C
LEU
101
n
101
LEU
101
C
PRO
102
n
102
PRO
102
C
LEU
103
n
103
LEU
103
C
ILE
104
n
104
ILE
104
C
LYS
105
n
105
LYS
105
C
SER
106
n
106
SER
106
C
TYR
107
n
107
TYR
107
C
LEU
108
n
108
LEU
108
C
PHE
109
n
109
PHE
109
C
GLN
110
n
110
GLN
110
C
LEU
111
n
111
LEU
111
C
LEU
112
n
112
LEU
112
C
GLN
113
n
113
GLN
113
C
GLY
114
n
114
GLY
114
C
LEU
115
n
115
LEU
115
C
ALA
116
n
116
ALA
116
C
PHE
117
n
117
PHE
117
C
CYS
118
n
118
CYS
118
C
HIS
119
n
119
HIS
119
C
SER
120
n
120
SER
120
C
HIS
121
n
121
HIS
121
C
ARG
122
n
122
ARG
122
C
VAL
123
n
123
VAL
123
C
LEU
124
n
124
LEU
124
C
HIS
125
n
125
HIS
125
C
ARG
126
n
126
ARG
126
C
ASP
127
n
127
ASP
127
C
LEU
128
n
128
LEU
128
C
LYS
129
n
129
LYS
129
C
PRO
130
n
130
PRO
130
C
GLN
131
n
131
GLN
131
C
ASN
132
n
132
ASN
132
C
LEU
133
n
133
LEU
133
C
LEU
134
n
134
LEU
134
C
ILE
135
n
135
ILE
135
C
ASN
136
n
136
ASN
136
C
THR
137
n
137
THR
137
C
GLU
138
n
138
GLU
138
C
GLY
139
n
139
GLY
139
C
ALA
140
n
140
ALA
140
C
ILE
141
n
141
ILE
141
C
LYS
142
n
142
LYS
142
C
LEU
143
n
143
LEU
143
C
ALA
144
n
144
ALA
144
C
ASP
145
n
145
ASP
145
C
PHE
146
n
146
PHE
146
C
GLY
147
n
147
GLY
147
C
LEU
148
n
148
LEU
148
C
ALA
149
n
149
ALA
149
C
ARG
150
n
150
ARG
150
C
ALA
151
n
151
ALA
151
C
PHE
152
n
152
PHE
152
C
n
153
153
C
n
154
154
C
n
155
155
C
n
156
156
C
n
157
157
C
n
158
158
C
n
159
159
C
n
160
160
C
n
161
161
C
n
162
162
C
n
163
163
C
VAL
164
n
164
VAL
164
C
THR
165
n
165
THR
165
C
LEU
166
n
166
LEU
166
C
TRP
167
n
167
TRP
167
C
TYR
168
n
168
TYR
168
C
ARG
169
n
169
ARG
169
C
ALA
170
n
170
ALA
170
C
PRO
171
n
171
PRO
171
C
GLU
172
n
172
GLU
172
C
ILE
173
n
173
ILE
173
C
LEU
174
n
174
LEU
174
C
LEU
175
n
175
LEU
175
C
GLY
176
n
176
GLY
176
C
CYS
177
n
177
CYS
177
C
LYS
178
n
178
LYS
178
C
TYR
179
n
179
TYR
179
C
TYR
180
n
180
TYR
180
C
SER
181
n
181
SER
181
C
THR
182
n
182
THR
182
C
ALA
183
n
183
ALA
183
C
VAL
184
n
184
VAL
184
C
ASP
185
n
185
ASP
185
C
ILE
186
n
186
ILE
186
C
TRP
187
n
187
TRP
187
C
SER
188
n
188
SER
188
C
LEU
189
n
189
LEU
189
C
GLY
190
n
190
GLY
190
C
CYS
191
n
191
CYS
191
C
ILE
192
n
192
ILE
192
C
PHE
193
n
193
PHE
193
C
ALA
194
n
194
ALA
194
C
GLU
195
n
195
GLU
195
C
MET
196
n
196
MET
196
C
VAL
197
n
197
VAL
197
C
THR
198
n
198
THR
198
C
ARG
199
n
199
ARG
199
C
ARG
200
n
200
ARG
200
C
ALA
201
n
201
ALA
201
C
LEU
202
n
202
LEU
202
C
PHE
203
n
203
PHE
203
C
PRO
204
n
204
PRO
204
C
GLY
205
n
205
GLY
205
C
ASP
206
n
206
ASP
206
C
SER
207
n
207
SER
207
C
GLU
208
n
208
GLU
208
C
ILE
209
n
209
ILE
209
C
ASP
210
n
210
ASP
210
C
GLN
211
n
211
GLN
211
C
LEU
212
n
212
LEU
212
C
PHE
213
n
213
PHE
213
C
ARG
214
n
214
ARG
214
C
ILE
215
n
215
ILE
215
C
PHE
216
n
216
PHE
216
C
ARG
217
n
217
ARG
217
C
THR
218
n
218
THR
218
C
LEU
219
n
219
LEU
219
C
GLY
220
n
220
GLY
220
C
THR
221
n
221
THR
221
C
PRO
222
n
222
PRO
222
C
ASP
223
n
223
ASP
223
C
GLU
224
n
224
GLU
224
C
VAL
225
n
225
VAL
225
C
VAL
226
n
226
VAL
226
C
TRP
227
n
227
TRP
227
C
PRO
228
n
228
PRO
228
C
GLY
229
n
229
GLY
229
C
VAL
230
n
230
VAL
230
C
THR
231
n
231
THR
231
C
SER
232
n
232
SER
232
C
MET
233
n
233
MET
233
C
PRO
234
n
234
PRO
234
C
ASP
235
n
235
ASP
235
C
TYR
236
n
236
TYR
236
C
LYS
237
n
237
LYS
237
C
PRO
238
n
238
PRO
238
C
SER
239
n
239
SER
239
C
PHE
240
n
240
PHE
240
C
PRO
241
n
241
PRO
241
C
LYS
242
n
242
LYS
242
C
TRP
243
n
243
TRP
243
C
ALA
244
n
244
ALA
244
C
ARG
245
n
245
ARG
245
C
GLN
246
n
246
GLN
246
C
ASP
247
n
247
ASP
247
C
PHE
248
n
248
PHE
248
C
SER
249
n
249
SER
249
C
LYS
250
n
250
LYS
250
C
VAL
251
n
251
VAL
251
C
VAL
252
n
252
VAL
252
C
PRO
253
n
253
PRO
253
C
PRO
254
n
254
PRO
254
C
LEU
255
n
255
LEU
255
C
ASP
256
n
256
ASP
256
C
GLU
257
n
257
GLU
257
C
ASP
258
n
258
ASP
258
C
GLY
259
n
259
GLY
259
C
ARG
260
n
260
ARG
260
C
SER
261
n
261
SER
261
C
LEU
262
n
262
LEU
262
C
LEU
263
n
263
LEU
263
C
SER
264
n
264
SER
264
C
GLN
265
n
265
GLN
265
C
MET
266
n
266
MET
266
C
LEU
267
n
267
LEU
267
C
HIS
268
n
268
HIS
268
C
TYR
269
n
269
TYR
269
C
ASP
270
n
270
ASP
270
C
PRO
271
n
271
PRO
271
C
ASN
272
n
272
ASN
272
C
LYS
273
n
273
LYS
273
C
ARG
274
n
274
ARG
274
C
ILE
275
n
275
ILE
275
C
SER
276
n
276
SER
276
C
ALA
277
n
277
ALA
277
C
LYS
278
n
278
LYS
278
C
ALA
279
n
279
ALA
279
C
ALA
280
n
280
ALA
280
C
LEU
281
n
281
LEU
281
C
ALA
282
n
282
ALA
282
C
HIS
283
n
283
HIS
283
C
PRO
284
n
284
PRO
284
C
PHE
285
n
285
PHE
285
C
PHE
286
n
286
PHE
286
C
GLN
287
n
287
GLN
287
C
ASP
288
n
288
ASP
288
C
VAL
289
n
289
VAL
289
C
THR
290
n
290
THR
290
C
LYS
291
n
291
LYS
291
C
PRO
292
n
292
PRO
292
C
VAL
293
n
293
VAL
293
C
PRO
294
n
294
PRO
294
C
HIS
295
n
295
HIS
295
C
LEU
296
n
296
LEU
296
C
ARG
297
n
297
ARG
297
C
LEU
298
n
298
LEU
298
C
author_and_software_defined_assembly
PISA
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
C
N
GLY
13
A
N
GLY
13
C
O
GLY
16
A
O
GLY
16
C
N
ALA
21
A
N
ALA
21
C
O
VAL
30
A
O
VAL
30
C
N
LYS
33
A
N
LYS
33
C
O
LEU
78
A
O
LEU
78
C
O
VAL
79
A
O
VAL
79
C
N
LEU
67
A
N
LEU
67
C
N
GLN
85
A
N
GLN
85
C
O
ILE
135
A
O
ILE
135
C
N
LEU
134
A
N
LEU
134
C
O
LYS
142
A
O
LYS
142
1
C
CG
ARG
36
A
CG
ARG
36
1
Y
1
C
CD
ARG
36
A
CD
ARG
36
1
Y
1
C
NE
ARG
36
A
NE
ARG
36
1
Y
1
C
CZ
ARG
36
A
CZ
ARG
36
1
Y
1
C
NH1
ARG
36
A
NH1
ARG
36
1
Y
1
C
NH2
ARG
36
A
NH2
ARG
36
1
Y
1
C
LEU
37
A
LEU
37
1
Y
1
C
ASP
38
A
ASP
38
1
Y
1
C
THR
39
A
THR
39
1
Y
1
C
GLU
40
A
GLU
40
1
Y
1
C
THR
41
A
THR
41
1
Y
1
C
GLU
42
A
GLU
42
1
Y
1
C
GLY
43
A
GLY
43
1
Y
1
C
GLY
153
A
GLY
153
1
Y
1
C
VAL
154
A
VAL
154
1
Y
1
C
PRO
155
A
PRO
155
1
Y
1
C
VAL
156
A
VAL
156
1
Y
1
C
ARG
157
A
ARG
157
1
Y
1
C
THR
158
A
THR
158
1
Y
1
C
TYR
159
A
TYR
159
1
Y
1
C
THR
160
A
THR
160
1
Y
1
C
HIS
161
A
HIS
161
1
Y
1
C
GLU
162
A
GLU
162
1
Y
1
C
VAL
163
A
VAL
163
1
Y
1
14.12
2.30
115.30
129.42
C
C
C
CA
CB
CG
LEU
LEU
LEU
166
166
166
N
1
C
LYS
6
-65.57
94.49
1
C
GLU
8
179.20
158.23
1
C
GLU
12
-178.80
141.47
1
C
PRO
45
-35.02
119.48
1
C
ALA
95
-48.62
-18.03
1
C
ARG
126
75.19
-6.69
1
C
ASP
127
-147.44
46.33
1
C
TYR
179
-108.77
64.92
0.27
0.19
0.19
2.2
8.0
15038
10.0
99.0
RANDOM
1
THROUGHOUT
2
OTHER
2.2
8.0
76
2350
22
0
2252
0.013
1.70
2.200
50.000
1W0X
15044
0.000
0.08000
1
3.300
99.0
refinement
X-PLOR
3.1
CYCLIN-DEPENDENT KINASE 2 (E.C.2.7.1.37)
Crystal structure of human CDK2 in complex with the inhibitor olomoucine.
1
N
N
2
N
N
3
N
N
C
PRO
45
A
PRO
45
HELX_P
C
GLU
57
A
GLU
57
1
1
13
C
LEU
87
A
LEU
87
HELX_P
C
ALA
95
A
ALA
95
1
2
9
C
PRO
100
A
PRO
100
HELX_P
C
SER
120
A
SER
120
1
3
21
C
LYS
129
A
LYS
129
HELX_P
C
GLN
131
A
GLN
131
5
4
3
C
GLY
147
A
GLY
147
HELX_P
C
PHE
152
A
PHE
152
1
5
6
C
ALA
170
A
ALA
170
HELX_P
C
LEU
175
A
LEU
175
1
6
6
C
THR
182
A
THR
182
HELX_P
C
ARG
199
A
ARG
199
1
7
18
C
SER
207
A
SER
207
HELX_P
C
GLY
220
A
GLY
220
1
8
14
C
GLY
229
A
GLY
229
HELX_P
C
MET
233
A
MET
233
5
9
5
C
ASP
247
A
ASP
247
HELX_P
C
VAL
252
A
VAL
252
1
10
6
C
ASP
256
A
ASP
256
HELX_P
C
LEU
267
A
LEU
267
1
11
12
C
SER
276
A
SER
276
HELX_P
C
ALA
282
A
ALA
282
1
12
7
C
HIS
283
A
HIS
283
HELX_P
C
VAL
289
A
VAL
289
5
13
7
TRANSFERASE
PROTEIN KINASE INHIBITORS, CYCLIN-DEPENDENT KINASE, CELL CYCLE REGULATION, CANCER, TRANSFERASE, SERINE/THREONINE -PROTEIN KINASE, ATP-BINDING
CDK2_HUMAN
UNP
1
P24941
1
298
1W0X
1
298
P24941
C
1
1
298
5
3
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
C
PHE
4
A
PHE
4
C
GLY
13
A
GLY
13
C
GLY
16
A
GLY
16
C
ASN
23
A
ASN
23
C
VAL
29
A
VAL
29
C
LYS
34
A
LYS
34
C
LYS
75
A
LYS
75
C
GLU
81
A
GLU
81
C
LEU
66
A
LEU
66
C
THR
72
A
THR
72
C
GLN
85
A
GLN
85
C
ASP
86
A
ASP
86
C
LEU
133
A
LEU
133
C
ILE
135
A
ILE
135
C
ILE
141
A
ILE
141
C
LEU
143
A
LEU
143
BINDING SITE FOR RESIDUE OLO C 1299
Software
8
C
ILE
10
A
ILE
10
8
1_555
C
ALA
31
A
ALA
31
8
1_555
C
GLU
81
A
GLU
81
8
1_555
C
PHE
82
A
PHE
82
8
1_555
C
LEU
83
A
LEU
83
8
1_555
C
ASP
86
A
ASP
86
8
1_555
C
GLN
131
A
GLN
131
8
1_555
C
LEU
134
A
LEU
134
8
1_555
19
P 21 21 21